Related Experiment Videos
[Chemotherapy for small cell lung cancer]
M Fukuoka1, M Takada, N Masuda
1Department of Internal Medicine, Osaka Prefectural Habikino Hospital.
Nihon Kyobu Shikkan Gakkai Zasshi
|December 1, 1993
Summary
This study compared chemotherapy regimens for small cell lung cancer (SCLC). Alternating chemotherapy (CAV/PE) showed higher response rates and survival, while G-CSF support improved dose intensity and outcomes in dose-intensive chemotherapy.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Small cell lung cancer (SCLC) requires effective treatment strategies.
- Optimizing chemotherapy regimens and supportive care is crucial for improving patient outcomes.
Purpose of the Study:
- To compare alternating chemotherapy (cyclophosphamide, doxorubicin, vincristine/cisplatin, etoposide) with standard regimens in SCLC.
- To evaluate the efficacy of dose-intensive weekly chemotherapy with or without granulocyte-colony stimulating factor (G-CSF) in SCLC.
Main Methods:
- A randomized phase III trial compared cyclophosphamide, doxorubicin, vincristine (CAV), cisplatin and etoposide (PE), and alternating CAV/PE in 288 SCLC patients.
- A separate randomized study assessed the addition of G-CSF to weekly CODE (cyclophosphamide, Oncovin, doxorubicin, etoposide) chemotherapy in 63 SCLC patients.
Main Results:
- The PE and CAV/PE regimens demonstrated significantly higher response rates (78% and 76%) compared to CAV (55%).
- CAV/PE showed a trend towards superior median survival time (MST), though this advantage diminished after adjusting for prognostic factors.
- G-CSF support reduced neutropenic fever and increased dose intensity, leading to a significantly longer MST (58 weeks) compared to CODE alone (36 weeks).
Conclusions:
- Alternating chemotherapy (CAV/PE) is a reasonable approach for SCLC management.
- Dose-intensive weekly chemotherapy supported by G-CSF may improve outcomes for patients with extensive-stage SCLC (ED-SCLC).